Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 3/20 | 0.39 |
| ▸ | MLYCD | O95822 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201251 | 0.91 | HDAC4 (0.40) | ROCK1AOC3PRMT3CARM1PRMT6 | |
| SCHEMBL18563035 | 0.87 | CARM1 (0.37) | ROCK1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL16201252 | 0.84 | PRMT3 (0.42) | ROCK1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL16201226 | 0.83 | AOC3 (0.41) | ALDH1A1AOC3PRMT3CARM1PRMT6 | |
| SCHEMBL18563036 | 0.82 | CARM1 (0.37) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL16201250 | 0.80 | CARM1 (0.45) | HPGDALDH1A1PRMT3CARM1PRMT6 | |
| SCHEMBL18563037 | 0.79 | CARM1 (0.36) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL16201281 | 0.79 | PRMT6 (0.43) | HPGDPRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL16068186 | 0.79 | MOK (0.44) | HPGDALDH1A1MAPTL3MBTL1AOC3 | |
| SCHEMBL16201186 | 0.78 | CARM1 (0.46) | ALDH1A1ROCK1PRMT3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9732041-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732041-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346761-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323537-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HPGD 828/4885ALDH1A1 686/4885MAPT 1449/4885 |
| US-20170057926-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HPGD 828/4885ALDH1A1 686/4885MAPT 1449/4885 |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HPGD 581/4885ALDH1A1 895/4885MAPT 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.